10-QPeriod: Q1 FY2025

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 1, 2025For Securities:BSX

Summary

Boston Scientific Corporation reported strong financial results for the first quarter ended March 31, 2025, with net sales increasing by 20.9% year-over-year to $4.663 billion. This growth was driven by robust commercial execution across its business segments, notably the Electrophysiology business unit and its Farapulse™ Pulsed Field Ablation System. The company reported a net income attributable to common stockholders of $674 million, or $0.45 per diluted share, a significant increase from the prior year. The company also highlighted its strategic acquisitions and upcoming integrations, including the recent completion of Cortex, Inc. and the pending acquisitions of SoniVie Ltd. and Intera Oncology, Inc. These moves underscore Boston Scientific's commitment to expanding its product portfolio and market reach, particularly in high-growth areas like cardiology and peripheral interventions. The company maintains a strong liquidity position and is in compliance with its financial covenants, demonstrating financial stability amidst ongoing global economic uncertainties.

Financial Highlights

49 data points
Beta

Revenue

$4.66B

68.8% Gross Margin

Net Income

$674.00M

14.5% Net Margin

EPS (Diluted)

$0.45

Total Assets

$40.14B

Cash & Equivalents

$725.00M

Free Cash Flow

$354.00M

Financial Statements
Beta
Revenue$4.66B
Cost of Revenue$1.45B
Gross Profit$3.21B
SG&A Expenses$1.60B
Operating Expenses$2.29B
Operating Income$921.00M
Interest Expense$82.00M
Net Income$674.00M
EPS (Basic)$0.46
EPS (Diluted)$0.45
Shares Outstanding (Basic)1.48B
Shares Outstanding (Diluted)1.49B

Key Highlights

  • 1Net sales surged by 20.9% to $4.663 billion for the first quarter of 2025, driven by strong global commercial execution.
  • 2Net income attributable to common stockholders was $674 million, or $0.45 per diluted share, up from $495 million, or $0.33 per diluted share, in the prior year.
  • 3The Electrophysiology business unit, particularly the Farapulse™ Pulsed Field Ablation System, was a key growth driver.
  • 4Acquisition activity remains robust with the completion of Cortex, Inc. and pending acquisitions of SoniVie Ltd. and Intera Oncology, Inc.
  • 5Gross profit margin improved slightly to 68.8% due to higher-margin product sales.
  • 6SG&A expenses increased but decreased as a percentage of net sales, reflecting improved operational leverage.
  • 7The company reported a strong liquidity position with $725 million in unrestricted cash and cash equivalents and no outstanding amounts under its revolving credit facility.

Frequently Asked Questions

The significant increase in net sales was primarily driven by strong commercial execution across all business segments, with notable growth in the Electrophysiology business unit, largely attributed to the successful adoption of the Farapulse™ Pulsed Field Ablation System. Overall operational net sales growth was 22.2%, reflecting strong organic growth and contributions from recent acquisitions.

Boston Scientific continues to pursue a robust acquisition strategy to expand its product portfolio. In the first quarter of 2025, they completed the acquisition of Cortex, Inc. They also announced definitive agreements to acquire SoniVie Ltd. and Intera Oncology, Inc., expected to close in the second quarter of 2025. These acquisitions are strategically focused on bolstering their cardiology and peripheral intervention offerings.

Boston Scientific demonstrates a strong financial position. They reported $725 million in unrestricted cash and cash equivalents as of March 31, 2025. Furthermore, they had no amounts outstanding under their $2.750 billion revolving credit facility, indicating ample liquidity. The company is also in compliance with its financial covenants, with a leverage ratio of 2.21 times compared to a maximum permitted of 4.75 times.

The company is involved in various ongoing legal proceedings, including patent litigation related to its Synergy™ Stent System, product liability litigation concerning transvaginal surgical mesh, and governmental investigations into its operations, particularly concerning alleged Foreign Corrupt Practices Act (FCPA) violations in Vietnam. While the company accrues for probable and estimable losses, the outcomes of these matters remain uncertain and could materially impact financial results.